Phaseline

Companies › Sanaria

Sanaria: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PfSPZ-LARC2 Vaccine
Double deletion of MEI2 and LINUP genes in Plasmodium falciparum NF54 sporozoites - arrest
LINUP, MEI2Phase 2Malaria (Plasmodium Falciparum); Malaria FalciparumFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07385287PfSPZ-LARC2 VaccinePhase 2Malaria (Plasmodium Falciparum)Infectious diseaseFeb 2027
NCT06862453PfSPZ-LARC2 VaccinePhase 1Malaria FalciparumInfectious diseaseAug 2027
NCT07675785PfSPZ-LARC2 VaccinePhase 2Malaria (Plasmodium Falciparum)Infectious diseaseJul 2028

Targets

LINUP (1) MEI2 (1)

Companies with the same targets

–

Companies built like this

Eveliqure Biotechnologies CastleVax Medicago Brii Biosciences SIGA Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.